Alpha Rose, a biotech company focused on developing personalized medicine for rare genetic diseases, has successfully raised over $1 million.
Driven by the founder’s firsthand experience with his daughter’s rare genetic diagnosis, Alpha Rose is aiming to develop a portfolio of more medicines, creating efficiencies and scale through iterative learning, AI and robotics.
According to Alpha Rose, their proprietary ASO platform minimizes drug development safety concerns. They also have their lead product heading towards a clinical trial.
With data showing that 200 million children worldwide suffer from rare genetic diseases, with only 5% having available treatments.
Alpha Rose is aiming at these rare genetic diseases that have been historically overlooked.
Alpha Rose has successfully raised this amount with the support of over 39 investors, a testament to their funding achievements on StartEngine from a valuation of $12.09 million.
You can become part of this growth by investing with a minimum contribution of US$599.40 or 1.35 per share.
Alpha Rose is a biotech company focused on developing personalized medicine for neurodevelopmental conditions using ASO technology.
If you click on a link and make a purchase we may receive a small commission. Learn more. All content on this site is provided with no warranties, express or implied. Use any information at your own risk. Privacy Policy.
Discover more from BITVoxy
Subscribe to get the latest posts sent to your email.
)